Merrill Lynch maintains Gilead at neutral rating

Gilead Sciences Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating after Gilead reported better-than-expected third-quarter earnings of $0.38 a share versus Merrill Lynch and consensus estimates of $0.37 a share. Third-quarter earnings were driven by strong Truvada sales, but guidance for the fourth-quarter shows a possible decline in HIV franchise sales. Even if HIV sales beat expectations, Merrill Lynch said the company has low pipeline visibility. Shares of the Foster City, Calif.-based biopharmaceutical company were down $2.22, or 4.60%, at $46.01 on volume of 11,686,195 shares versus the three-month running average of 3,636,390 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.